Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 plus oxaliplatin, 5-fluorouracil and calcium folinate in advanced pancreatic cancer (phase II, single-arm)
ChiCTR2300078203Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CPO-120 in pancreatic cancer (PC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall survival (OS). Started Dec 2023; status: recruiting.
02
Drugs
CPO-120
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300078203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078203.